Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Insulin signaling in health and disease
Alan R. Saltiel
Alan R. Saltiel
Published January 4, 2021
Citation Information: J Clin Invest. 2021;131(1):e142241. https://doi.org/10.1172/JCI142241.
View: Text | PDF
Review Series

Insulin signaling in health and disease

  • Text
  • PDF
Abstract

The molecular mechanisms of cellular insulin action have been the focus of much investigation since the discovery of the hormone 100 years ago. Insulin action is impaired in metabolic syndrome, a condition known as insulin resistance. The actions of the hormone are initiated by binding to its receptor on the surface of target cells. The receptor is an α2β2 heterodimer that binds to insulin with high affinity, resulting in the activation of its tyrosine kinase activity. Once activated, the receptor can phosphorylate a number of intracellular substrates that initiate discrete signaling pathways. The tyrosine phosphorylation of some substrates activates phosphatidylinositol-3-kinase (PI3K), which produces polyphosphoinositides that interact with protein kinases, leading to activation of the kinase Akt. Phosphorylation of Shc leads to activation of the Ras/MAP kinase pathway. Phosphorylation of SH2B2 and of Cbl initiates activation of G proteins such as TC10. Activation of Akt and other protein kinases produces phosphorylation of a variety of substrates, including transcription factors, GTPase-activating proteins, and other kinases that control key metabolic events. Among the cellular processes controlled by insulin are vesicle trafficking, activities of metabolic enzymes, transcriptional factors, and degradation of insulin itself. Together these complex processes are coordinated to ensure glucose homeostasis.

Authors

Alan R. Saltiel

×

Figure 1

The insulin receptor, its substrates, and its activation of kinase cascades.

Options: View larger image (or click on image) Download as PowerPoint
The insulin receptor, its substrates, and its activation of kinase casca...
(A) The insulin receptor is a disulfide-linked, α/β heterodimer glycoprotein that resides largely on the cell surface. The α subunit binds to insulin with high affinity, alleviating PTP-mediated repression of the β subunit’s tyrosine kinase activity by inducing close proximity between the β subunits, permitting transphosphorylation on tyrosines in three β subunit domains. Phosphorylation of three crucial tyrosines leads to full activation of the receptor kinase. Once activated, the receptor kinase can phosphorylate exogenous substrates that act as adaptors: IRS-1–IRS-4 and Shc. Both are recruited to the juxtamembrane region via their PTB domains. SH2B2 is recruited to the kinase region’s triple phosphorylation motif via its SH2 domain, serving as an adaptor protein for the substrate Cbl. (B) Activation of kinase cascades. Once phosphorylated, IRS and Shc activate lipid and protein kinases. IRS proteins are phosphorylated on tyrosines within specific motifs, recruiting the p85 subunit of PI3K, which binds to IRS through its SH2 domain. This results in activation of the p110 catalytic domain to generate polyphosphoinositides such as PI-(3,4,5)trisphosphate (PIP3). These phosphoinositides can be degraded by the PI phosphatases PTEN and SHIP2. PIP3 interacts with proteins containing PH domains, notably PDK1 and Akt. Once recruited to the plasma membrane, PDK1 and mTORC2 phosphorylate and activate Akt, which can phosphorylate a number of substrates, including the GAP proteins RalGAPA, AS160, and TSC2, as well as Foxo proteins, GSK3, and others. Upon phosphorylation, Shc interacts with the SH2/SH3 adaptor protein Grb2, which is constitutively associated with the GEF SOS. SOS is thus recruited to the plasma membrane, and catalyzes the exchange of GTP for GDP on Ras. In its active, GTP-bound state, Ras interacts with the protein kinase Raf, leading to activation of the MAPK cascade through sequential phosphorylation of MEK and ERK.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts